Analysts Offer Predictions for Cytosorbents Co.’s FY2024 Earnings (NASDAQ:CTSO)

Cytosorbents Co. (NASDAQ:CTSOGet Rating) – Analysts at Jefferies Financial Group cut their FY2024 EPS estimates for Cytosorbents in a research report issued on Tuesday, May 3rd. Jefferies Financial Group analyst F. Pinal now forecasts that the medical research company will earn $0.35 per share for the year, down from their previous forecast of $0.38. Jefferies Financial Group also issued estimates for Cytosorbents’ FY2025 earnings at $0.61 EPS.

Other equities research analysts also recently issued reports about the company. StockNews.com started coverage on Cytosorbents in a report on Thursday, March 31st. They issued a “sell” rating for the company. B. Riley decreased their price target on Cytosorbents from $7.00 to $6.00 in a report on Wednesday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cytosorbents currently has an average rating of “Buy” and a consensus price target of $9.67.

CTSO stock opened at $2.12 on Thursday. Cytosorbents has a twelve month low of $1.80 and a twelve month high of $9.80. The business has a 50 day simple moving average of $3.04 and a 200-day simple moving average of $4.08.

Cytosorbents (NASDAQ:CTSOGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The medical research company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.06). Cytosorbents had a negative net margin of 56.90% and a negative return on equity of 34.49%. During the same period last year, the company earned ($0.10) earnings per share.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Cytosorbents by 2.8% in the fourth quarter. BlackRock Inc. now owns 2,631,210 shares of the medical research company’s stock valued at $11,024,000 after acquiring an additional 72,418 shares during the period. Skylands Capital LLC lifted its holdings in Cytosorbents by 5.9% in the fourth quarter. Skylands Capital LLC now owns 1,946,374 shares of the medical research company’s stock valued at $8,155,000 after acquiring an additional 108,833 shares during the period. Avenir Corp lifted its holdings in Cytosorbents by 28.1% in the fourth quarter. Avenir Corp now owns 1,787,275 shares of the medical research company’s stock valued at $7,489,000 after acquiring an additional 391,890 shares during the period. Neuberger Berman Group LLC lifted its holdings in Cytosorbents by 48.8% in the third quarter. Neuberger Berman Group LLC now owns 1,260,574 shares of the medical research company’s stock valued at $10,203,000 after acquiring an additional 413,485 shares during the period. Finally, Granahan Investment Management Inc. MA lifted its holdings in Cytosorbents by 15.0% in the third quarter. Granahan Investment Management Inc. MA now owns 1,154,561 shares of the medical research company’s stock valued at $9,375,000 after acquiring an additional 151,015 shares during the period. 40.98% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents (Get Rating)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.

Read More

Earnings History and Estimates for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.